Should tall cell thyroid cancers be evaluated differently from well-differentiated thyroid cancers?

Area of Science:

• Endocrinology
• Oncology
• Surgical Pathology

Background:

• Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy.
• Tall cell variant (TCV) of PTC is an aggressive subtype with distinct clinical and pathological features.
• Understanding TCV's characteristics is vital for effective management and improved patient prognosis.

Purpose of the Study:

• To investigate the clinical features of papillary thyroid carcinoma, specifically the tall cell variant (TCV).
• To evaluate the long-term outcomes and survival rates of patients with TCV.
• To analyze surgical experiences and treatment strategies for TCV.

Main Methods:

• Retrospective analysis of 33 patients diagnosed with TCV between August 2012 and March 2018.
• Examination of demographic, clinical, and pathological features.
• Assessment of long-term outcomes, including survival rates and recurrence patterns.

Main Results:

• TCV is more prevalent in females (75.8%) with a mean age of 55.2 years.
• Common clinical presentation includes neck swelling (75.7%).
• Aggressive pathological features observed: multifocality (36.3%), capsular invasion (69.7%), extrathyroidal extension (39.4%), and lymph node metastasis (30.3%).
• High rates of distant metastasis (39.4%) and disease recurrence were noted.
• Disease-free survival was 57.6%, with a mean total survival of 42.4 months.

Conclusions:

• TCV is associated with larger tumor size, multifocality, extrathyroidal spread, and lymph node involvement.
• Aggressive surgical approaches and meticulous follow-up are recommended for TCV management.
• TCV requires a distinct treatment strategy due to its aggressive nature and poorer prognosis.